Pancreatic Cancer Research

ResearcherUniversity of InsubriaActive in the last 2 years

Michele Ghidini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5435-1218; OpenAlex author ID A5004680827. Sources: OpenAlex.

Their work

Papers
20 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 20

  1. Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes. Co-author DOI 10.1016/j.ctrv.2026.103170↗
  2. Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses. Co-author DOI 10.3390/cancers18091344↗
  3. Comparative Efficacy of 21 Treatment Strategies for Resectable Pancreatic Cancer: A Network Meta-Analysis. Last author DOI 10.3390/cancers16183203↗
  4. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. First author DOI 10.1007/s12029-023-00923-6↗
  5. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  6. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. Last author DOI 10.1186/s12876-023-02853-w↗
  7. Locoregional Therapies and Remodeling of Tumor Microenvironment in Pancreatic Cancer. Last author DOI 10.3390/ijms241612681↗
  8. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. First author DOI 10.1016/j.radonc.2021.09.001↗
  9. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Co-author DOI 10.3390/cancers13112797↗
  10. The Role of Positron Emission Tomography/Computed Tomography (PET/CT) for Staging and Disease Response Assessment in Localized and Locally Advanced Pancreatic … Co-author DOI 10.3390/cancers13164155↗
  11. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Last author DOI 10.3390/cancers13174396↗
  12. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Co-author DOI 10.3390/genes12010033↗
  13. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. First author DOI 10.21037/jgo.2018.12.08↗
  14. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and … First author DOI 10.3390/cancers11040484↗
  15. Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers11040550↗
  16. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? Co-author DOI 10.3390/cancers11081095↗
  17. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. Co-author DOI 10.1016/j.hpb.2017.07.005↗
  18. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirub… Co-author DOI 10.1007/s00280-011-1680-2↗
  19. Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Co-author DOI 10.1159/000324865↗
  20. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Co-author DOI 10.2217/pgs.11.109↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fausto Petrelli · 12 shared papers, 2017–2026 · strength 1.89
  2. Gianluca Tomasello · 11 shared papers, 2017–2026 · strength 1.69
  3. Lorenzo Dottorini · 3 shared papers, 2024–2026 · strength 0.80
  4. Shelize Sadrudin Khakoo · 3 shared papers, 2019–2023 · strength 0.41
  5. Alberto Zaniboni · 2 shared papers, 2019–2026 · strength 0.39
  6. Angelica Petrillo · 3 shared papers, 2019–2021 · strength 0.35
  7. Gianpaolo Balzano · 2 shared papers, 2012–2026 · strength 0.33
  8. Sara Cherri · 1 shared paper, 2026 · strength 0.29
  9. Ester Oneda · 1 shared paper, 2026 · strength 0.29
  10. Michele Reni · 4 shared papers, 2011–2023 · strength 0.27
  11. Umberto Peretti · 1 shared paper, 2023 · strength 0.19
  12. Marina Macchini · 1 shared paper, 2023 · strength 0.19
  13. Giulia Orsi · 1 shared paper, 2023 · strength 0.19
  14. Stefano Cascinu · 1 shared paper, 2023 · strength 0.19
  15. Antonio Facciorusso · 1 shared paper, 2023 · strength 0.18
  16. Anna Maria Ierardi · 1 shared paper, 2023 · strength 0.18
  17. Gianpaolo Carrafiello · 1 shared paper, 2023 · strength 0.18
  18. Maria Caterina De Grandis · 1 shared paper, 2023 · strength 0.18
  19. Sandro Barni · 2 shared papers, 2017–2019 · strength 0.18
  20. Daniele Eliseo Dondossola · 1 shared paper, 2021 · strength 0.14
  21. Maria Picchio · 1 shared paper, 2021 · strength 0.14
  22. Jens Claus Hahne · 1 shared paper, 2020 · strength 0.13
  23. Gaël S. Roth · 1 shared paper, 2021 · strength 0.12
  24. Jean–Marc Phelip · 1 shared paper, 2021 · strength 0.12
  25. Ferdinando De Vita · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.